-
1
-
-
33644831033
-
Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: A clinical trial coordinated by the Eastern Cooperative Oncology Group
-
Eastern Cooperative Oncology Group
-
Rajkumar SV, Blood E, Vesole D, Fonseca R, Greipp PR; Eastern Cooperative Oncology Group. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol. 2006; 24(3):431-436.
-
(2006)
J Clin Oncol
, vol.24
, Issue.3
, pp. 431-436
-
-
Rajkumar, S.V.1
Blood, E.2
Vesole, D.3
Fonseca, R.4
Greipp, P.R.5
-
2
-
-
0036843032
-
Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma
-
Rajkumar SV, Hayman S, Gertz MA, et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol. 2002;20(21):4319-4323.
-
(2002)
J Clin Oncol
, vol.20
, Issue.21
, pp. 4319-4323
-
-
Rajkumar, S.V.1
Hayman, S.2
Gertz, M.A.3
-
3
-
-
84860907057
-
Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma
-
Kumar S, Flinn I, Richardson PG, et al. Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. Blood. 2012;119(19):4375-4382.
-
(2012)
Blood
, vol.119
, Issue.19
, pp. 4375-4382
-
-
Kumar, S.1
Flinn, I.2
Richardson, P.G.3
-
4
-
-
77954618168
-
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma
-
Richardson PG, Weller E, Lonial S, et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood. 2010;116(5): 679-686.
-
(2010)
Blood
, vol.116
, Issue.5
, pp. 679-686
-
-
Richardson, P.G.1
Weller, E.2
Lonial, S.3
-
5
-
-
0345447210
-
Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy
-
Kane RC, Bross PF, Farrell AT, Pazdur R. Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy. Oncologist. 2003;8(6):508-513.
-
(2003)
Oncologist
, vol.8
, Issue.6
, pp. 508-513
-
-
Kane, R.C.1
Bross, P.F.2
Farrell, A.T.3
Pazdur, R.4
-
6
-
-
0037973279
-
A phase 2 study of bortezomib in relapsed, refractory myeloma
-
Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003;348(26): 2609-2617.
-
(2003)
N Engl J Med
, vol.348
, Issue.26
, pp. 2609-2617
-
-
Richardson, P.G.1
Barlogie, B.2
Berenson, J.3
-
7
-
-
36349023319
-
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma
-
Multiple Myeloma (010) Study Investigators
-
Dimopoulos M, Spencer A, Attal M, et al Multiple Myeloma (010) Study Investigators. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med. 2007;357(21): 2123-2132.
-
(2007)
N Engl J Med
, vol.357
, Issue.21
, pp. 2123-2132
-
-
Dimopoulos, M.1
Spencer, A.2
Attal, M.3
-
8
-
-
36349010285
-
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America
-
Multiple Myeloma (009) Study Investigators
-
Weber DM, Chen C, Niesvizky R, et al Multiple Myeloma (009) Study Investigators. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med. 2007; 357(21):2133-2142.
-
(2007)
N Engl J Med
, vol.357
, Issue.21
, pp. 2133-2142
-
-
Weber, D.M.1
Chen, C.2
Niesvizky, R.3
-
9
-
-
84856719479
-
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study
-
International Myeloma Working Group
-
Kumar SK, Lee JH, Lahuerta JJ, et al International Myeloma Working Group. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia. 2012;26(1):149-157.
-
(2012)
Leukemia
, vol.26
, Issue.1
, pp. 149-157
-
-
Kumar, S.K.1
Lee, J.H.2
Lahuerta, J.J.3
-
10
-
-
67349228774
-
Development of the pan-DAC inhibitor panobinostat (LBH589): Successes and challenges
-
Atadja P. Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges. Cancer Lett. 2009;280(2):233-241.
-
(2009)
Cancer Lett
, vol.280
, Issue.2
, pp. 233-241
-
-
Atadja, P.1
-
11
-
-
33751172982
-
Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells
-
Catley L, Weisberg E, Kiziltepe T, et al. Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells. Blood. 2006;108(10):3441-3449.
-
(2006)
Blood
, vol.108
, Issue.10
, pp. 3441-3449
-
-
Catley, L.1
Weisberg, E.2
Kiziltepe, T.3
-
12
-
-
83455251274
-
A phase lb study of oral panobinostat and IV bortezomib in relapsed or relapsed and refractory multiple myeloma
-
San-Miguel JF, Richardson PGG, Sezer O, et al. A phase lb study of oral panobinostat and IV bortezomib in relapsed or relapsed and refractory multiple myeloma. J Clin Oncol. 2011;29(15-suppl):8075.
-
(2011)
J Clin Oncol
, vol.29
, Issue.15 SUPPL.
, pp. 8075
-
-
San-Miguel, J.F.1
Richardson, P.G.G.2
Sezer, O.3
-
13
-
-
18244428600
-
European Group for Blood and Marrow Transplant. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by highdose therapy and haemopoietic stem cell transplantation
-
Myeloma Subcommittee of the EBMT
-
Bladé J, Samson D, Reece D, et al Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by highdose therapy and haemopoietic stem cell transplantation. Br J Haematol. 1998;102(5):1115-1123.
-
(1998)
Br J Haematol
, vol.102
, Issue.5
, pp. 1115-1123
-
-
Bladé, J.1
Samson, D.2
Reece, D.3
-
14
-
-
84988241358
-
International uniform response criteria for multiple myeloma
-
International Myeloma Working Group
-
Durie BG, Harousseau JL, Miguel JS, et al International Myeloma Working Group. International uniform response criteria for multiple myeloma. Leukemia. 2006;20(9):1467-1473.
-
(2006)
Leukemia
, vol.20
, Issue.9
, pp. 1467-1473
-
-
Durie, B.G.1
Harousseau, J.L.2
Miguel, J.S.3
-
15
-
-
79955977910
-
Consensus recommendations for the uniform reporting of clinical trials: Report of the International Myeloma Workshop Consensus Panel 1
-
International Myeloma Workshop Consensus Panel 1
-
Rajkumar SV, Harousseau JL, Durie B, et al; International Myeloma Workshop Consensus Panel 1. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood. 2011;117(18):4691-4695.
-
(2011)
Blood
, vol.117
, Issue.18
, pp. 4691-4695
-
-
Rajkumar, S.V.1
Harousseau, J.L.2
Durie, B.3
-
16
-
-
0038509089
-
Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: A report of the International Myeloma Working Group
-
International Myeloma Working Group
-
International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003;121(5):749-757.
-
(2003)
Br J Haematol
, vol.121
, Issue.5
, pp. 749-757
-
-
-
17
-
-
79751534825
-
Rapid recovery from panobinostat (LBH589)-induced thrombocytopenia in mice involves a rebound effect of bone marrow megakaryocytes
-
Giver CR, Jaye DL, Waller EK, Kaufman JL, Lonial S. Rapid recovery from panobinostat (LBH589)-induced thrombocytopenia in mice involves a rebound effect of bone marrow megakaryocytes. Leukemia. 2011;25(2):362-365.
-
(2011)
Leukemia
, vol.25
, Issue.2
, pp. 362-365
-
-
Giver, C.R.1
Jaye, D.L.2
Waller, E.K.3
Kaufman, J.L.4
Lonial, S.5
-
18
-
-
79953725710
-
Deciphering the molecular and biologic processes that mediate histone deacetylase inhibitorinduced thrombocytopenia
-
Bishton MJ, Harrison SJ, Martin BP, et al. Deciphering the molecular and biologic processes that mediate histone deacetylase inhibitorinduced thrombocytopenia. Blood. 2011;117(13):3658-3668.
-
(2011)
Blood
, vol.117
, Issue.13
, pp. 3658-3668
-
-
Bishton, M.J.1
Harrison, S.J.2
Martin, B.P.3
-
19
-
-
84862511317
-
Panobinostat (LBH589)-induced acetylation of tubulin impairs megakaryocyte maturation and platelet formation
-
Iancu-Rubin C, Gajzer D, Mosoyan G, Feller F, Mascarenhas J, Hoffman R. Panobinostat (LBH589)-induced acetylation of tubulin impairs megakaryocyte maturation and platelet formation. Exp Hematol. 2012;40(7):564-574.
-
(2012)
Exp Hematol
, vol.40
, Issue.7
, pp. 564-574
-
-
Iancu-Rubin, C.1
Gajzer, D.2
Mosoyan, G.3
Feller, F.4
Mascarenhas, J.5
Hoffman, R.6
-
20
-
-
84861804180
-
Vantage 095: Vorinostat in combination with bortezomib in salvage multiple myeloma patients: Final study results of a global phase 2b trial
-
ASH Annual Meeting Abstracts Abstract 480
-
Siegel DS, Dimopoulos MA, Yoon S, et al. Vantage 095: Vorinostat in combination with bortezomib in salvage multiple myeloma patients: final study results of a global phase 2b trial [ASH Annual Meeting Abstracts]. Blood. 2011;118(21). Abstract 480.
-
(2011)
Blood
, vol.118
, Issue.21
-
-
Siegel, D.S.1
Dimopoulos, M.A.2
Yoon, S.3
-
21
-
-
84877622448
-
Pomalidomide plus lowdose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02
-
Intergroupe Francophone du Myélome
-
Leleu X, Attal M, Arnulf B, et al Intergroupe Francophone du Myélome. Pomalidomide plus lowdose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02. Blood. 2013;121(11):1968- 1975.
-
(2013)
Blood
, vol.121
, Issue.11
, pp. 1968-1975
-
-
Leleu, X.1
Attal, M.2
Arnulf, B.3
-
22
-
-
84884702467
-
Pomalidomide (POM) with or without low-dose dexamethasone (LoDEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Outcomes in pts refractory to lenalidomide (LEN) and/or bortezomib (BORT)
-
Vij R, Richardson PGG, Jagannath S, et al. Pomalidomide (POM) with or without low-dose dexamethasone (LoDEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Outcomes in pts refractory to lenalidomide (LEN) and/or bortezomib (BORT). J Clin Oncol. 2012; 30(15-suppl):8016.
-
(2012)
J Clin Oncol
, vol.30
, Issue.15 SUPPL.
, pp. 8016
-
-
Vij, R.1
Richardson, P.G.G.2
Jagannath, S.3
-
23
-
-
84880091523
-
Phase II study of infusional carfilzomib in patients with relapsed or refractory multiple myeloma
-
ASH Annual Meeting Abstracts Abstract 947
-
Lendvai N, Landau H, Lesokhin A, et al. Phase II study of infusional carfilzomib in patients with relapsed or refractory multiple myeloma [ASH Annual Meeting Abstracts]. Blood. 2012;120(21). Abstract 947.
-
(2012)
Blood
, vol.120
, Issue.21
-
-
Lendvai, N.1
Landau, H.2
Lesokhin, A.3
-
24
-
-
85081792956
-
Phase III study of panobinostat with bortezomib and dexamethasone in patients with relapsed multiple myeloma (PANORAMA 1)
-
Presented at abstract e18572
-
San-Miguel JF, Moreau P, Yoon S, et al. Phase III study of panobinostat with bortezomib and dexamethasone in patients with relapsed multiple myeloma (PANORAMA 1). Presented at American Society of Clinical Oncology Annual Meeting. June 1-5, 2012; Chicago, IL [abstract e18572].
-
American Society of Clinical Oncology Annual Meeting. June 1-5, 2012; Chicago, IL
-
-
San-Miguel, J.F.1
Moreau, P.2
Yoon, S.3
-
25
-
-
34447121281
-
New drugs for myeloma
-
Richardson PG, Mitsiades C, Schlossman R, Munshi N, Anderson K. New drugs for myeloma. Oncologist. 2007;12(6):664-689.
-
(2007)
Oncologist
, vol.12
, Issue.6
, pp. 664-689
-
-
Richardson, P.G.1
Mitsiades, C.2
Schlossman, R.3
Munshi, N.4
Anderson, K.5
|